Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that with regards to Heparin litigation, in July 2011, the U.S. District Court for the Northern District of Ohio ruled…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the company is executing a recall of COLLEAGUE infusion pumps through July 13, 2012 by offering its customers an…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that several shareholder derivative actions are ongoing against the company.
In May 2010, a shareholder derivative action was brought on behalf…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission the next trial in Propofol litigation is scheduled for August 2011.
The company is a defendant, along with others, in numerous…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that a trial date for the first of Heparin cases in Ohio is scheduled for March 2011.
In connection with the…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is fully cooperating with the request through a subpoena from the Office of the U.S. Attorney of the…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that a trial date for the first of Heparin cases in Illinois is scheduled in May 2011.
In connection with the…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the company remains a a defendant, along with others, in 11 lawsuits brought in various U.S. federal courts alleging…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the company and Teva Pharmaceuticals USA, Inc. (Teva) intends to appeal a US$500 million adverse decision in Nevada.
The company…
Baxter International Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that a trial date for the first of cases in connection with the recall of heparin products in the United…